



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)




PRODUCT INFORMATION



Erlotinib-d₆ (hydrochloride)

Item No. 22101

CAS Registry No.: 1189953-78-3
Formal Name: N-(3-ethynylphenyl)-6,7-bis[2-(methoxy-d₃)ethoxy]-4-quinazolinamine, monohydrochloride
MF: C₂₂H₁₇D₆N₃O₄ • HCl
FW: 435.9
Chemical Purity: ≥95% (Erlotinib)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₆); ≤1% d₀
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Erlotinib-d₆ (hydrochloride) contains six deuterium atoms located on the methoxy group. It is intended for use as an internal standard for the quantification of erlotinib (Item No. 10483) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Erlotinib-d₆ (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the erlotinib-d₆ (hydrochloride) in the solvent of choice. Erlotinib-d₆ (hydrochloride) is slightly soluble in methanol and DMSO (heated).

Description

Erlotinib is a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity (IC₅₀ = 2.5 μM).^{1,2} This inhibits tumor growth in human head and neck carcinoma (HN5) tumor xenografts in mice with an ED₅₀ value of 9 mg/kg.¹ Erlotinib also suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC₅₀ = 4.6 μM) and JAK2 mutant JAK2^{V617F} (IC₅₀ = 5 μM), which is associated with polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia.^{3,4} Formulations containing erlotinib are used to treat certain forms of cancer, including non-small cell lung cancer.^{5,6}

References

1. Ciardiello, F. and Tortora, G. *Clin. Cancer Res.* **7**(10), 2958-2970 (2001).
2. Greulich, H., Chen, T.H., Feng, W., et al. *PLoS Med.* **2**(11) (2005).
3. Yamasaki, F., Zhang, D., Bartholomeusz, C., et al. *Mol. Cancer Ther.* **6**(8), 2168-2177 (2007).
4. Li, Z., Xu, M., Xing, S., et al. *J. Biol. Chem.* **282**(6), 3428-3432 (2007).
5. Herbst, R.S. and Bunn, P.A., Jr. *Clin. Cancer Res.* **9**(16), 5813-5824 (2003).
6. Gerber, D.E. *Drug Dev. Res.* **69**(6), 359-372 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/02/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM